David R. Lynch MD, PhD

Dr. Lynch maintains a dynamic program focused on the rare disease Friedreich's ataxia (FA), a progressive neurogenetic condition found in approximately one in 50,000 people worldwide. More specifically, the research led by Dr. Lynch spans clinical, translational, and basic science research efforts on FA that include conducting double-blind clinical trials, identifying biomarkers, and leading mechanistic studies in animal and cellular models of FA.

The research conducted by Dr. Lynch and his lab team have led to a greater understanding of the metabolic dysfunction underlying FA. Their work has led to the creation of a patient database as well as a pipeline of more than 20 drug candidates that represent potential new therapies. Dr. Lynch is currently working with pharmaceutical industry partners to develop drug candidates as well as biomarkers for FA.